Hisamitsu Pharmaceutical Co Inc (HTSUF)

OTHER OTC:HTSUF

HTSUF

Hisamitsu Pharmaceutical Co

RESEARCH TOOLSreports

Hisamitsu Pharmaceutical Co (HTSUF) Price & Analysis

7 Followers

HTSUF Stock Chart & Stats

$28.79

-$0.66(0.00%)

At close: Apr 23 4:00 PM EDT

$28.79

-$0.66(0.00%)

Day’s Range― - ―

52-Week Range$24.75 - $34.59

Previous CloseN/A

Volume30.00

Average Volume (3M)0.00

Market Cap

$2.76B

Enterprise Value$324.11B

Total Cash (Recent Filing)$118.13B

Total Debt (Recent Filing)$2.65B

Price to Earnings (P/E)15.4

Beta0.23

Next Earnings

Apr 13, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield2.54%

Share Statistics

EPS (TTM)0.43

Shares Outstanding75,164,894

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.23

Price to Book (P/B)1.12

Price to Sales (P/S)1.99

P/FCF Ratio60.52

Enterprise Value/Market Cap117.43

Enterprise Value/Revenue2.09

Enterprise Value/Gross Profit3.54

Enterprise Value/Ebitda15.37

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)1.87

Revenue Forecast (FY)$1.08B

Bulls Say, Bears Say

Bulls Say

Revenue & MarginsSustained revenue expansion coupled with high gross and solid EBITDA margins indicates durable earnings power. Strong unit economics and pricing flexibility support reinvestment in R&D and marketing, improving resilience to demand cycles and underpinning long-term cash generation.

Balance Sheet StrengthA very high equity ratio and low leverage give the company long‑term financial flexibility. This conservative capital structure reduces refinancing risk, supports investment or acquisitions without heavy debt, and preserves capacity to sustain dividends through downturns.

Cash Flow GenerationConsistent operating cash flow and positive free cash flow show the business self-funds operations and growth. Reliable cash conversion enables ongoing product investment, supports shareholder returns, and cushions the company against short‑term funding stress.

Bears Say

Product Concentration RiskHeavy reliance on transdermal and topical franchises concentrates economic exposure. Technological shifts, intensified competition, or therapeutic substitution in these categories could disproportionately affect revenue, and limited therapeutic diversification reduces resilience over the medium term.

Rising LiabilitiesAn uptick in total liabilities, if unchecked, could erode the firm's conservative balance sheet. Faster liability growth can constrain strategic flexibility, increase interest and covenant risk, and limit the company's ability to fund R&D or M&A without altering its leverage profile.

Net Margin CeilingWhile margins are healthy, the net margin lags gross and EBITDA, suggesting remaining cost or operating‑leverage headroom. Persistent pressure on SG&A, pricing or reimbursement could prevent further net margin expansion and limit the translation of revenue growth into bottom‑line gains.

Hisamitsu Pharmaceutical Co News

Hisamitsu to Cancel All Treasury Shares Ahead of Planned Share Consolidation

The latest announcement is out from Hisamitsu Pharmaceutical Co ( ($JP:4530) ). Hisamitsu Pharmaceutical will cancel 4,763,348 of...

23d ago

Hisamitsu Pharma Sets Shareholder Vote on Share Consolidation Ahead of Planned Delisting

Hisamitsu Pharmaceutical Co ( ($JP:4530) ) has issued an update. Hisamitsu Pharmaceutical’s board has resolved to convene an...

23d ago

Taiyo Kosan Wins Control of Hisamitsu Pharmaceutical After Successful Tender Offer

Hisamitsu Pharmaceutical Co ( ($JP:4530) ) has issued an announcement. Taiyo Kosan Co., Inc. has successfully completed its...

1M ago

Hisamitsu Sets Record Date for Potential MBO-Linked Shareholder Meeting

The latest update is out from Hisamitsu Pharmaceutical Co ( ($JP:4530) ). Hisamitsu Pharmaceutical will set February 28,...

2M ago

TAIYO KOSAN Amends Tender Offer Filing for Hisamitsu Pharmaceutical After U.S. Antitrust Waiting Period

Hisamitsu Pharmaceutical Co ( ($JP:4530) ) has shared an announcement. Hisamitsu Pharmaceutical and its affiliate TAIYO KOSAN Co.,...

2M ago

Hisamitsu President’s Vehicle TAIYO KOSAN Launches Tender Offer to Boost Stake

The latest update is out from Hisamitsu Pharmaceutical Co ( ($JP:4530) ). TAIYO KOSAN CO., INC. has launched...

3M ago

Hisamitsu Board Backs CEO-Led MBO and Recommends Shareholders Tender Stock

The latest announcement is out from Hisamitsu Pharmaceutical Co ( ($JP:4530) ). Hisamitsu Pharmaceutical’s board of directors has...

3M ago

Hisamitsu Posts Modest Sales Growth, Withdraws Forecast as MBO and Delisting Loom

Hisamitsu Pharmaceutical Co ( ($JP:4530) ) has provided an announcement. Hisamitsu Pharmaceutical reported consolidated net sales of ¥114.5...

3M ago

Hisamitsu Pharmaceutical Scraps Year-End Dividend as Board Backs Privatization Tender Offer

Hisamitsu Pharmaceutical Co ( ($JP:4530) ) just unveiled an update. Hisamitsu Pharmaceutical has revised its dividend forecast for...

3M ago

Hisamitsu Withdraws Earnings Forecast Amid MBO-Linked Tender Offer and Planned Delisting

An update from Hisamitsu Pharmaceutical Co ( ($JP:4530) ) is now available. Hisamitsu Pharmaceutical has withdrawn its consolidated...

3M ago

HTSUF FAQ

What was Hisamitsu Pharmaceutical Co Inc’s price range in the past 12 months?

Hisamitsu Pharmaceutical Co Inc lowest stock price was $24.75 and its highest was $34.59 in the past 12 months.

What is Hisamitsu Pharmaceutical Co Inc’s market cap?

Hisamitsu Pharmaceutical Co Inc’s market cap is $2.76B.

When is Hisamitsu Pharmaceutical Co Inc’s upcoming earnings report date?

Hisamitsu Pharmaceutical Co Inc’s upcoming earnings report date is Apr 13, 2026 which is in 8 days.

How were Hisamitsu Pharmaceutical Co Inc’s earnings last quarter?

Hisamitsu Pharmaceutical Co Inc released its earnings results on Jan 06, 2026. The company reported $0.431 earnings per share for the quarter, missing the consensus estimate of $137.1 by -$136.669.

Is Hisamitsu Pharmaceutical Co Inc overvalued?

According to Wall Street analysts Hisamitsu Pharmaceutical Co Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Hisamitsu Pharmaceutical Co Inc pay dividends?

Hisamitsu Pharmaceutical Co Inc pays a Notavailable dividend of $0.416 which represents an annual dividend yield of 2.54%. See more information on Hisamitsu Pharmaceutical Co Inc dividends here

What is Hisamitsu Pharmaceutical Co Inc’s EPS estimate?

Hisamitsu Pharmaceutical Co Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Hisamitsu Pharmaceutical Co Inc have?

Hisamitsu Pharmaceutical Co Inc has 75,164,894 shares outstanding.

What happened to Hisamitsu Pharmaceutical Co Inc’s price movement after its last earnings report?

Hisamitsu Pharmaceutical Co Inc reported an EPS of $0.431 in its last earnings report, missing expectations of $137.1. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Hisamitsu Pharmaceutical Co Inc?

Currently, no hedge funds are holding shares in HTSUF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Hisamitsu Pharmaceutical Co Inc

Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals, quasi-drugs, and medical devices in Japan. The company provides external pain relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; and BUTENALOCK, a remedy for athlete's foot, as well as ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, transdermal analgesic anti-inflammatory drug; patches for female hormone, asthma treatment, and treatment for overactive bladders. In addition, the company manufactures and sells drugs under MOHRUS TAPE, MOHRUS PAP XR, FENTOS Tapes, NEOXY Tapes, Abstral, ALLESAGA Tapes, HARUROPI Tapes, and MENOAID Combipatch. Further, it provides HFT-290, a transdermal patch for cancer pain. The company sells its products in the United States and Asia. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan.